Neurol. praxi. 2025;26(5):366-370 | DOI: 10.36290/neu.2025.017
New treatment options for myasthenia gravis
- Neuromuskulární centrum ERN, Neurologická klinika FN Brno
Myasthenia gravis is a serious autoimmune, antibody-mediated disorder of neuromuscular transmission. The condition is pathogenetically linked to thymic disease. It typically presents with skeletal muscle fatigability (including that of respiratory muscles) that fluctuates depending on fatigue and time of day. The diagnostic work-up is based on the clinical presentation, antibody testing, electrophysiology, and imaging of the thymus. Cholinesterase inhibitors are the main relief drugs. The essence of the pathogenetically-oriented treatment is thymectomy and administration of corticosteroids and immunosuppressants. Currently, novel therapeutic strategies are beginning to be used in the treatment: C5 complement inhibitors and FcRn inhibitors. The use of strategies against B cell lines is still a subject of controversy or clinical trials.
Keywords: myasthenia gravis, treatment, complement inhibitors, FcRn inhibitors.
Received: January 29, 2025; Revised: March 4, 2025; Accepted: March 5, 2025; Prepublished online: March 5, 2025; Published: November 6, 2025 Show citation
References
- Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. Lancet Neurol. 2023;22:383-394.
Go to original source... - De Bleecker JL, Remiche G, Alonso-Jiménez A, et al. Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol. Belg. 2024;124:1371-1383. Go to original source...
- Dewilde S, Phillips G, Paci S, et al. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies. Adv. Ther. 2023;40:4377-4394. Go to original source...
- Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. Neurol. Clin. 2018;36:311-337. Go to original source...
- Gilhus NE. Treatment considerations in myasthenia gravis for the pregnant patient. Expert Rev. Neurother. 2023;23:169-177. Go to original source...
- Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. Eur. J. Neurol. 2024;31:e16229. Go to original source...
- Habib AA, Zhao C, Aban I, et al. Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. Lancet Neurol. 2025;24:117-127. Go to original source...
- Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Neurol. 2023;22:395-406. Go to original source...
- Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526-536. Go to original source...
- Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976-986. Go to original source...
- Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: A United States health claims analysis. Muscle Nerve. 2023;67:297-305. Go to original source...
- Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Complement Inhibition for the Treatment of Myasthenia Gravis. ImmunoTargets Ther. 2020;9:317-331. Go to original source...
- Mevius A, Jöres L, Biskup J, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul. Disord. NMD. 2023;33:324-333. Go to original source...
- Nair SS, Jacob S. Novel Immunotherapies for Myasthenia Gravis. ImmunoTargets Ther. 2023;12:25-45. Go to original source...
- Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. Neurology. 2022;98:e376-e389. Go to original source...
- Pane C, Di Stefano V, Cuomo N, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J. Neurol. 2024;271:6209-6219. Go to original source...
- Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. JAMA Neurol. 2022;79:1105-1112. Go to original source...
- Polák P, Penka M, Smejkal P, et al. Treatment with rituximab as an opportunity for the prevention of infectious complications. Vnitř Lék. 2016;62:398-405.
- Saccà F, Pane C, Espinosa PE, et al. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis. Eur. J. Neurol. 2023. Go to original source...
- Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. NEJM Evid. 2022; 1: EVIDoa2100066. Go to original source...
- Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther. Adv. Neurol. Disord. 2023;16:17562864231213240. Go to original source...
- Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. N. Engl. J. Med. 2016;375:511-522. Go to original source...